An observational study in Alzheimer Disease, Neurodegenerative Diseases and Magnetic Resonance Imaging, sponsored by Norwegian University of Science and Technology. Recruiting at 1 site in Norway. Open to participants aged 55 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Norwegian University of Science and Technology · Observational
Semantic AD
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
This study's planned enrollment of 30 is below the median of 200 across 814 observational studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 48 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants will be recruited from the region of Trøndelag, Norway. The study population will include individuals with cognitive symptoms as well as cognitively healthy, age- and sex-matched controls. Recruitment will take place through memory clinics and primary care services. All participants will undergo standardized assessments and data collection as specified in the study protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnosis of other neurodegenerative diseases such as Parkinson's disease or ALS.
7T MRI contraindications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients above 65 diagnosed with Alzheimer's Disease according to appropriate ICD-criterias.
Device: 7T MRI · Device: EEG · Biological: Blood samples · Biological: Stool samples · Diagnostic Test: Neuropsychologic test (MoCA)
Age- and gender-matched control group.
Device: 7T MRI · Device: EEG · Biological: Blood samples · Biological: Stool samples · Diagnostic Test: Neuropsychologic test (MoCA)
Resting and activity-based MRI. Dring activity based MRI, the participant will complete tasks testing semantic memory.
Also known as: Magnetic Resonance imaging
Resting-state EEG
Also known as: Electrophysiology
Blood samples taken for analysis of central blood biomarkers.
Stool samples collected to identify distinct gut-microbiota compositions between the groups.
Also known as: Fecal Speciments
Map cognition with clinically well-established neuropsychology test
Understand which individual differences are observed among patients with Alzheimer's disease (AD).
This outcome will characterize individual variability among patients diagnosed with Alzheimer's disease based on clinical symptoms, cognitive assessments, neuroimaging findings (7T MRI), electrophysiological data (EEG), and biological samples (blood and stool). The goal is to identify patterns or subtypes that may reflect distinct disease mechanisms or progression profiles.
Time frame: From enrollment to end of follow-up at 1 year.
Compare changes in the brain, blood, and stool samples between dementia patients and healthy controls.
Assess differences between dementia patients and cognitively healthy controls using multimodal data, including 7T MRI for brain structure, EEG, blood biomarkers, and gut microbiome profiles from stool samples. The aim is to identify biological and neurological markers associated with dementia-related changes.
Time frame: From project enrollment to end of follow-up at 1 year.
Understand which individuals with mild cognitive impairment (MCI) go on to develop Alzheimer's disease (AD).
Identify early clinical, neuroimaging, and biological markers associated with progression from MCI to AD. This research question aims to improve early diagnosis and risk stratification in individuals with MCI.
Time frame: From enrollment to the end of follow-up time at 1 year.
Compare brain changes in patients with Alzheimer's disease (AD) to those with other types of dementia.
This outcome will investigate brain changes in patients with Alzheimer's disease compared to those with other dementia types using the different modalities included in the project.
Time frame: From project encrollment to end of follow-up at 1 year.
Plan to share: No — All data will be anonymized.
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Dec 2027, 50 months after the start.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 50 months is below that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norwegian University of Science and Technology →